Roivant Sciences Ltd. (ROIV) NASDAQ
28.21
-0.885(-3.04%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
28.21
-0.885(-3.04%)
Currency In USD
| Previous Close | 29.09 |
| Open | 28.71 |
| Day High | 28.87 |
| Day Low | 27.93 |
| 52-Week High | 32.79 |
| 52-Week Low | 10.71 |
| Volume | 3.69M |
| Average Volume | 8.4M |
| Market Cap | 20.29B |
| PE | -52.23 |
| EPS | -0.54 |
| Moving Average 50 Days | 28.61 |
| Moving Average 200 Days | 22.41 |
| Change | -0.89 |
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
GlobeNewswire Inc.
Mar 03, 2026 9:15 PM GMT
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed pate
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
GlobeNewswire Inc.
Mar 03, 2026 12:00 PM GMT
FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026Priority Review supported by positive Phase 3 VALOR results, the first positive 52-week placebo-controlled trial in derma
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
GlobeNewswire Inc.
Feb 06, 2026 12:00 PM GMT
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001)All brepocitinib 45 mg patients achieved a clin